Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta
![Photo: ARND WIEGMANN/REUTERS / X90184](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13400289.ece/ALTERNATES/schema-16_9/doc7i4qfbgros3f1k0ldkw.jpg)
Although sclerosis drug Kesimpta has been on somewhat of a worldwide victory tour, and generated sales of almost DKK 1.5bn (USD 230m) in the first three quarters of this year, the Danish Medicines Council is not convinced of its advantages.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst: Novartis's Kesimpta sales exceeded expectations
For subscribers
Novartis beats expectations for third quarter
For subscribers
Leo Pharma strongly criticizes Danish Medicines Council
For subscribers